FindMyKOL
Clinical trialNCT06049680RecruitingPhase 4Interventional

Safety Study of SMOFlipid to Evaluate the Risk of Developing EFAD and/or PNAC in Pediatric and Adult Patients

NCT06049680 is a phase 4 interventional trial sponsored by Fresenius Kabi. As of 21 Nov 2026, it is recruiting participants. It studies SMOFlipid® in Essential Fatty Acid Deficiency (EFAD), Malnutrition and 2 more conditions. The registry lists an enrollment of 100 participants at 6 sites in 1 country. The registry lists a start date of 28 Oct 2024 and a primary completion date of 30 Nov 2026.

SponsorFresenius Kabi →Enrollment100Essential Fatty Acid Deficiency (EFAD)MalnutritionMalnutrition, ChildParenteral Nutrition Associated Cholestasis
View the registry record on ClinicalTrials.gov

Key facts

Registry attributes as recorded on the ClinicalTrials.gov study record.

Key facts for NCT06049680
FieldValue
Registry IDNCT06049680
StatusRecruiting
PhasePhase 4
Study typeInterventional trial
Lead sponsorFresenius Kabi
Enrollment100
Registered sites6
Countries1
ConditionsEssential Fatty Acid Deficiency (EFAD), Malnutrition, Malnutrition, Child and Parenteral Nutrition Associated Cholestasis
DrugsSMOFlipid®
Start28 Oct 2024
Primary completion30 Nov 2026
Study completion31 Jan 2027
Last update posted22 Oct 2026

Registered summary

The lay summary the sponsor registered on ClinicalTrials.gov.

Evaluate the risk of developing EFAD and/or PNAC in adult and pediatric patients 1 month of age and older, who are anticipated to need 8 weeks or longer of parenteral nutrition treatment with SMOFlipid.

Investigators

The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

Georgia, United States1 site, 1 recruiting
  • Emory University Hospital

    Atlanta

    Recruiting
Illinois, United States1 site
  • the University of Chicago

    Chicago

    Terminated
Indiana, United States1 site, 1 recruiting
  • Riley Hospital for Children

    Indianapolis

    Recruiting
North Carolina, United States1 site
  • Duke University Medical Center

    Durham

    Not, yet, recruiting
Ohio, United States1 site, 1 recruiting
  • Nationwide Children's Hospital

    Columbus

    Recruiting
Pennsylvania, United States1 site, 1 recruiting
  • Children's Hospital of Pittsburgh of Upmc

    Pittsburgh

    Recruiting

United States, by state

AlaskaAKMaineMEVermontVTNew HampshireNHWashingtonWAMontanaMTNorth DakotaNDMinnesotaMNWisconsinWIMichiganMINew YorkNYMassachusettsMARhode IslandRIOregonORIdahoIDSouth DakotaSDIowaIAIllinois: 1 siteIL1Indiana: 1 site, 1 recruitingIN1Ohio: 1 site, 1 recruitingOH1Pennsylvania: 1 site, 1 recruitingPA1New JerseyNJConnecticutCTCaliforniaCANevadaNVWyomingWYNebraskaNEMissouriMOKentuckyKYWest VirginiaWVVirginiaVAMarylandMDDelawareDEArizonaAZUtahUTColoradoCOKansasKSArkansasARTennesseeTNNorth Carolina: 1 siteNC1South CarolinaSCNew MexicoNMOklahomaOKLouisianaLAMississippiMSAlabamaALGeorgia: 1 site, 1 recruitingGA1HawaiiHITexasTXFloridaFLDistrict of ColumbiaDC
Fewer sitesMore sites

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.

Linked drugs open the directory filtered to KOLs working with them.clinicaltrials.gov ↗

Questions about NCT06049680

Each answer restates registry values shown on this page.

What is NCT06049680?

NCT06049680 is a phase 4 interventional trial sponsored by Fresenius Kabi. It studies SMOFlipid® in Essential Fatty Acid Deficiency (EFAD), Malnutrition and 2 more conditions.

Is NCT06049680 recruiting?

As of 21 Nov 2026, it is recruiting participants. 4 of its 6 sites list their own status as recruiting.

Who leads NCT06049680?

The registry names Jeffrey Rudolph, MD (principal investigator, University of Pittsburgh) as the overall official.

Where does NCT06049680 run?

The registry lists 6 sites in 1 country. Every site with a stated country is in one country: United States.

Which drugs does NCT06049680 study?

The registered drug and biological interventions are SMOFlipid®.

When is NCT06049680 expected to complete?

The registry lists a primary completion date of 30 Nov 2026 and a study completion date of 31 Jan 2027. The sponsor last updated the record on 22 Oct 2026.

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.